Larry Shulman

Faculty MD Associate Director for Special Projects, Abramson Cancer Center

Director, Center for Global Cancer Medicine, Abramson Cancer Center

Professor, Department of Medicine, Perelman School of Medicine

Lawrence N. Shulman, MD, is an Innovation Faculty member at the Penn Center for Cancer Care Innovation (PC3I), Professor of Medicine at the Perelman School of Medicine, the Associate Director for Special Projects of the Abramson Cancer Center at the University of Pennsylvania, and Director of the Center for Global Cancer Medicine. In these capacities he helps to lead innovations in cancer care, both at Penn, and at global sites. He received his MD from Harvard Medical School and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Dr. Shulman is immediate past-Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. He serves on the Best Practices Committee of the National Comprehensive Cancer Network (NCCN). A specialist in the treatment of patients with breast cancer, his research includes innovations in cancer care delivery, and implementation of cancer treatment programs in low-resource settings.

Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor’s Advisory Council for Rwanda’s University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership. Dr. Shulman is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017.